BRAND NAME: MEFY-50
COMPOSITION: CLOMIPRAMINE 50 MG TABLETS
PACKING: 10×10
Clomipramine 50 mg Tablets are used in the treatment of Obsessive Compulsive Disorder; a disease in which an individual gets unwanted fears and anxieties that resultantly lead to repetitive actions or behaviors. It is given to patients who do not tolerate or do not respond to other treatments for depression or anxiety-related disorders. Available in the market with the brand name MEFY 50, this tablet is manufactured by the Best Clomipramine 50mg Tablet Manufacturer, Eridanus Healthcare.
Clomipramine comes from a group of medicines called antidepressants. This tricyclic antidepressant works by activating the function of chemical messengers called serotonin and noradrenaline in the brain which is necessary for managing mood, behavior, and emotions. In this way, Clomipramine helps in relieving depression, easing symptoms of anxiety (fear, panic, etc.), and calming the mood.
To ensure better relief from Clomipramine 50 mg Tablets, it is necessary for the user to take this medication in the same dose and duration as it is prescribed by the doctor. Moreover, it is important to keep in mind certain things to avoid the risks of any adverse or unwanted side effects:
Clomipramine 50 mg Tablets may not function well in patients with certain health conditions that are as follows:
Before taking Clomipramine 50 mg Tablets, it is crucial to inform your doctor if you are dealing with the above-mentioned health diseases to know the medication is safe for you.
With its powerful properties, Clomipramine 50 mg Tablets are considered an effective treatment for depression, obsessive-compulsive disorder, anxiety disorders, and panic disorders. Despite that, it may result in certain side effects for the user mainly because of over usage or inappropriate usage. Following are the side effects associated with this medication:
You must be logged in to post a review.
This will close in 0 seconds
Demo Description
This will close in 20 seconds
Reviews
There are no reviews yet.